THERIVA BIOLOGICS INC (TOVX) Fundamental Analysis & Valuation

NYSEARCA:TOVX • US87164U5083

0.1857 USD
0 (-2.06%)
Last: Mar 4, 2026, 03:30 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This TOVX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

Taking everything into account, TOVX scores 1 out of 10 in our fundamental rating. TOVX was compared to 520 industry peers in the Biotechnology industry. Both the profitability and financial health of TOVX have multiple concerns. TOVX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. TOVX Profitability Analysis

1.1 Basic Checks

  • In the past year TOVX has reported negative net income.
  • TOVX had a negative operating cash flow in the past year.
  • In the past 5 years TOVX always reported negative net income.
  • In the past 5 years TOVX always reported negative operating cash flow.
TOVX Yearly Net Income VS EBIT VS OCF VS FCFTOVX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • With a Return On Assets value of -82.49%, TOVX is not doing good in the industry: 68.65% of the companies in the same industry are doing better.
  • TOVX's Return On Equity of -278.22% is on the low side compared to the rest of the industry. TOVX is outperformed by 71.73% of its industry peers.
Industry RankSector Rank
ROA -82.49%
ROE -278.22%
ROIC N/A
ROA(3y)-44.56%
ROA(5y)-63.19%
ROE(3y)-72.49%
ROE(5y)-81.87%
ROIC(3y)N/A
ROIC(5y)N/A
TOVX Yearly ROA, ROE, ROICTOVX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for TOVX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TOVX Yearly Profit, Operating, Gross MarginsTOVX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. TOVX Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for TOVX has been reduced compared to 1 year ago.
  • Compared to 5 years ago, TOVX has more shares outstanding
  • Compared to 1 year ago, TOVX has a worse debt to assets ratio.
TOVX Yearly Shares OutstandingTOVX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
TOVX Yearly Total Debt VS Total AssetsTOVX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -16.03, we must say that TOVX is in the distress zone and has some risk of bankruptcy.
  • TOVX has a worse Altman-Z score (-16.03) than 80.38% of its industry peers.
  • A Debt/Equity ratio of 0.15 indicates that TOVX is not too dependend on debt financing.
  • The Debt to Equity ratio of TOVX (0.15) is worse than 64.04% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z -16.03
ROIC/WACCN/A
WACCN/A
TOVX Yearly LT Debt VS Equity VS FCFTOVX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 1.19 indicates that TOVX should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.19, TOVX is doing worse than 84.42% of the companies in the same industry.
  • A Quick Ratio of 1.19 indicates that TOVX should not have too much problems paying its short term obligations.
  • TOVX's Quick ratio of 1.19 is on the low side compared to the rest of the industry. TOVX is outperformed by 83.85% of its industry peers.
Industry RankSector Rank
Current Ratio 1.19
Quick Ratio 1.19
TOVX Yearly Current Assets VS Current LiabilitesTOVX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. TOVX Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 7.87% over the past year.
EPS 1Y (TTM)7.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.39%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, TOVX will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.10% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y16.55%
EPS Next 2Y36.8%
EPS Next 3Y24.87%
EPS Next 5Y18.1%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TOVX Yearly Revenue VS EstimatesTOVX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M
TOVX Yearly EPS VS EstimatesTOVX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -1K -2K -3K -4K

More info and screens

Find the best growth stocksShow best growing peers

1

4. TOVX Valuation Analysis

4.1 Price/Earnings Ratio

  • TOVX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year TOVX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TOVX Price Earnings VS Forward Price EarningsTOVX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TOVX Per share dataTOVX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

  • TOVX's earnings are expected to grow with 24.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.8%
EPS Next 3Y24.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TOVX Dividend Analysis

5.1 Amount

  • TOVX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TOVX Fundamentals: All Metrics, Ratios and Statistics

THERIVA BIOLOGICS INC

NYSEARCA:TOVX (3/4/2026, 3:30:40 PM)

0.1857

0 (-2.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-04
Inst Owners1.34%
Inst Owner Change189.27%
Ins Owners0.11%
Ins Owner Change0%
Market Cap6.63M
Revenue(TTM)N/A
Net Income(TTM)-29.55M
Analysts80
Price Target7.14 (3744.91%)
Short Float %16.12%
Short Ratio0.48
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.33%
Min EPS beat(2)38.93%
Max EPS beat(2)63.73%
EPS beat(4)3
Avg EPS beat(4)36.25%
Min EPS beat(4)-6.82%
Max EPS beat(4)63.73%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)33.15%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.62
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.87
EYN/A
EPS(NY)-3.76
Fwd EYN/A
FCF(TTM)-0.51
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS0
BVpS0.3
TBVpS-0.25
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -82.49%
ROE -278.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.56%
ROA(5y)-63.19%
ROE(3y)-72.49%
ROE(5y)-81.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.16%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.19
Quick Ratio 1.19
Altman-Z -16.03
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)94.56%
Cap/Depr(5y)59.96%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.39%
EPS Next Y16.55%
EPS Next 2Y36.8%
EPS Next 3Y24.87%
EPS Next 5Y18.1%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-34.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.46%
OCF growth 3YN/A
OCF growth 5YN/A

THERIVA BIOLOGICS INC / TOVX FAQ

What is the ChartMill fundamental rating of THERIVA BIOLOGICS INC (TOVX) stock?

ChartMill assigns a fundamental rating of 1 / 10 to TOVX.


What is the valuation status for TOVX stock?

ChartMill assigns a valuation rating of 1 / 10 to THERIVA BIOLOGICS INC (TOVX). This can be considered as Overvalued.


How profitable is THERIVA BIOLOGICS INC (TOVX) stock?

THERIVA BIOLOGICS INC (TOVX) has a profitability rating of 0 / 10.


How financially healthy is THERIVA BIOLOGICS INC?

The financial health rating of THERIVA BIOLOGICS INC (TOVX) is 2 / 10.